<DOC>
	<DOCNO>NCT00819091</DOCNO>
	<brief_summary>Efficacy safety BI 1356 compare placebo patient type 2 diabetes insufficient glycaemic control despite treatment sulfonylurea drug .</brief_summary>
	<brief_title>Randomized , Double-blind ( db ) , Placebo-controlled 18 Week Study Linagliptin ( BI 1356 ) Type 2 Diabetic Patients With Insufficient Glycaemic Control Sulfonylurea Drug</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : Patients 18 80 year old type 2 diabetes insufficient glycemic control [ glycosylated hemoglobin ( HbA1c 7 % 10 % ) ] despite therapy sulfonylurea drug Exclusion criterion : Myocardial infarction , stroke transient ischaemic attack last 6 month Treatment rosiglitazone , pioglitazone , GLP1 analogues , insulin antiobesity drug past 3 month Impaired hepatic function Severe renal impairment Current treatment systemic steroid Change thyroid hormone dosage Hereditary galactose intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>